CKMTF News Alert Carmat (CKMTF) 79.1300 02/14/2015 05:02:42

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Carmat (CKMTF) 79.1300 $CKMTF

Approval to Resume the First-in-Man Trial with CARMAT's Bioprosthetic Heart
Business Wire - Wed Jul 16, 1:00PM CDT
Regulatory News:

Cardiovascular Devices - Europe Clinicals Pipeline Product Analysis
M2 - Mon Jun 16, 6:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bbc87m/cardiovascular) has announced the addition of the "Cardiovascular Devices - Europe Clinicals Pipeline Product Analysis" report to their offering. This report provides Pipeline Analysis of Clinical Cardiovascular devices developed by several medical device companies located in Europe. This report includes a total of 52 companies with 120 products in development. This report includes a detailed company profile for each medical device company operating in Europe. The company profile includes key company facts, information on business description, mission statement and its location. Moreover, this report provides detailed analysis on all pipeline products of each company with information on the product category, indication, development stage, estimated approval date and pipeline territory of the product. Cardiovascular Device areas covered in this report include: - Cardiac Assist Devices - Cardiovascular Monitoring and Diagnostic Devices - Cardiac Rhythm Management Devices - Cardiovascular Surgery Devices - Electrophysiology Devices - Interventional Cardiology Devices - Peripheral Vascular Devices - Transcatheter Heart Valves This report is built using data and information from in-house analysis by the team of industry experts at Mordor Intelligence and from primary & secondary research. Why buy the report? - Develop strategies for market entry and expansion. - Identify your competition's product portfolio and create effective strategies to gain competitive advantage. - Design and develop business strategies by understanding current trends and developments. - Identify the status and estimated approval of your competitor's pipeline products and develop your business strategies. Companies Mentioned: - AFreeze GmbH - AVIDAL Vascular GmbH - Aachen Resonance GmbH - Acrostak (Schweiz) AG - Andramed GmbH - AorTech International plc - Arterion AB - B. Braun Melsungen AG - Carmat SAS - CellProthera - Dipylon Medical AB - Eurocor GmbH - Evasc Medical Systems - HighLife SAS - I.B.S. S.p.A. - ICON plc - Imaxdi. - Impulse Dynamics N.V. - Qvanteq AG - SAS Cormove - Sorin S.p.A. - Stentys, S.A - Symetis AG - Tioga Ltd - Tissue Regenix Ltd - Transcatheter Technologies GmbH - TrusTECH For more information visit http://www.researchandmarkets.com/research/bb...iovascular
MDSY: 2.97 (+0.02), ICLR: 60.01 (+0.38)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Diving Deep into the Whales' Activity with IBM Stock

Updated Category News Views 162

Understanding Recent Moves in IBM's Options Trading Recently, major financial players have made notable bullish moves concerning IBM. As we analyze the options trading history for International Business Machines, or IBM (NYSE: IBM), we uncover 12 unusual trades reflecting traders' sentiments. Trader Sentiment Breakdown Upon examining the trades, we find that 41% of the...

Continue Reading
Vestis Corporation Faces Important Lawsuit Deadline Ahead

Updated Category News Views 136

Critical Update on Vestis Corporation's Shareholder Lawsuit In a crucial development, the law firm Levi & Korsinsky has alerted investors regarding an impending deadline to participate in a class action lawsuit related to Vestis Corporation (NYSE: VSTS). This lawsuit aims to secure recoveries for investors who may have lost money due to alleged securities fraud. The lead...

Continue Reading
Equinor ASA Engages in Significant Share Buy-Back Activity

Updated Category News Views 90

Equinor ASA's Share Buy-Back Initiative Equinor ASA has recently made headlines with its latest share buy-back program, specifically the fourth tranche designated for the upcoming 2025 fiscal year. This strategic move aligns with the company's commitment to enhancing shareholder value and represents a proactive approach in managing its capital. Overview of the Buy-Back...

Continue Reading
Savoring the Flavor: QDOBA's National Burrito Day Celebration

Updated Category News Views 425

Celebrating National Burrito Day with QDOBA's Special Promotion QDOBA, a leading fast-casual Mexican restaurant, is kicking off National Burrito Day with an irresistible buy one, get one free offer, also known as "burrito insurance." This unique promotion is designed for the die-hard burrito lovers who believe that two burritos are better than one. In a fun twist, this...

Continue Reading
UK Competition Watchdog Challenges Google's Advertising Strategies

Updated Category News Views 109

UK Competition Watchdog Takes Action Against Google Recently, the UK's competition watchdog released significant findings about Google's practices in the advertising industry. The regulator has provisionally determined that Google (NASDAQ: GOOGL) has misused its dominant market position by managing both its publisher ad server and purchasing tools in a manner that...

Continue Reading